|
 |
| ORIGINAL ARTICLE |
|
| Year : 2010 | Volume
: 2
| Issue : 2 | Page : 86-88 |
|
|
Bimatoprost in the treatment of eyelash universalis alopecia areata
Teresa Ojeda Vila, Francisco M Camacho Martinez
Universital Hospital Virgen Macarena, Sevilla, Spain
| Date of Web Publication | 9-Mar-2011 |
Correspondence Address:
Teresa Ojeda Vila
Av. Dr. Fedriani s/n, 41009, Sevilla
Spain
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-7753.77511
 Abstract | | |
Objectives: To evaluate topical bimatoprost for eyelash growth in patients with alopecia areata (AA). Design: A 1-year retrospective study, bilateral eyelash alopecia. Materials and Methods: Forty-one subjects with AA universalis without ocular disease applied 0.03% bimatoprost to the eyelid margin once a day over the course of 1 year. Results: Thirty-seven subjects completed the study, one patient was eliminated due to conjunctivitis at the beginning of treatment, two patients developed conjunctivitis after 6 months of treatment, and a fourth did not follow directions. Researchers evaluated patients' eyelash growth every 4 months. We observed complete growth in 24.32%, moderate growth in 18.91%, slight growth in 27.02% and without response in 29.72%. Conclusion: Bimatoprost may be effective and safe in the treatment of eyelash AA. 43.24% of the patients had an acceptable cosmetic response (total and moderate growth). Limitations: Design without control. Keywords: Alopecia areata, bimatoprost, eyelash growth, prostaglandins
How to cite this article:
Vila TO, Camacho Martinez FM. Bimatoprost in the treatment of eyelash universalis alopecia areata. Int J Trichol 2010;2:86-8 |
| Introduction | |  |
Eyelash and eyebrow hypotrichosis is a common sign of alopecia areata (AA) totalis or universalis. This may cause decreased protection to the eyes and be cosmetically detrimental for patients. Prostaglandin analogs are the treatment for the glaucoma and elevated intraocular pressure (IOP). This treatment was incidentally found to treat hypotrichosis eyelashes. In 1997 Johnstone [1] reported the first case of hypertrichosis of the eyelashes by topical latanoprost and since then there have been several reports about the prostaglandin analogs as treatment to eyelashes in AA. In December 2008 the US Food and Drug Administration approved 0.03% bimatoprost solution (Latisse® ), identical to the ophthalmic solution for glaucoma treatment (Lumigan® ), for increasing eyelash length, thickness and darkness in patients with hypotrichosis of the eyelashes, [2] or persons who desire lengthy eyelashes.
| Materials and Methods | | |
We performed a 1-year retrospective study, and non-blinded with patients who had AA universalis. The study was developed in the Trichology Unit of Department of Dermatology of our Hospital where we treat the affected scalp and eyebrows with triamcinolone acetonide in saline solution at 0.125 every 3 months. The wash-out period for other treatments for the eyelashes AA was of four months. All subjects underwent an ophthalmic examination at the beginning and at the end of the study period. Patients applied topical 0.03% bimatoprost ophthalmic solution once a day at night on the eyelid margins bilaterally with a cotton applicator or their finger. They were seen for a follow-up examination every 4 months. In each review, including the basal visit, standardized digital photographs of the eyelashes were taken with a DermLite photo adapted to a Nikon Coolpix 4500, and every patient was evaluated by one investigator (T.O.) based on the picture taken in each visit.
A total of 41 patients were enrolled for the participation at the beginning, but we completed the study with 37 patients completed the study. Out of four patients excluded from the study one had conjunctivitis in the first month of treatment and two had after 6 months, none developed glaucoma.
The level of response was grouped in four categories: no regrowth, slight regrowth (1-29%), moderate (30-80%) and total (>80%). This classification was used and accepts by others authors in various studies. [3],[4] Investigators and subjects considered a cosmetic response to the moderate and total regrowth.
| Results | | |
There were 16 women and 25 men. Five patients were children less than 14 years, 38 had dark eyes and only three had pale eyes. At the end of the study (1-year follow up) 24.32% of subjects showed a complete regrowth, moderate growth was reported in 18.91%, slight growth in 27.02% whereas no response in remaining 29.72% [Figure 1]. Sixteen subjects (43.24%) got a cosmetically acceptable response [Figure 2] evaluated by the investigators and to the patients' satisfaction, and thirteen of these subjects got there growth of eyebrows. The average time needed to induce eyelash regrowth was from 4 to 8 months. Twenty-six subjects achieved a moderate or total regrowth [Figure 3] when seen for their 8-month check up. During the study, recurrences occurred in four patients (10.25%), all with a slight final response [Figure 4]. | Figure 3: Moderate regrowth after 8 months of treatment with bimatoprost
Click here to view |
Concerning side effects, three patients could not finish the study due to conjunctivitis, and all of them were then treated with latanoprost. We did not find any hyperpigmentation in the eyelid or iris, nor any cases of eyelid pruritus or redness.
Comments
AA is an autoimmune disease affecting any hair-bearing area of the body, including the eyelashes. Currently no therapies are specifically targeted for the regrowth of eyelashes in these patients.
Prostaglandin analogs (latanoprost, bimatoprost and tavoprost) have been well-established as an IOP lowering agents for glaucoma since 1996. [5] Bimatoprost has a chemical structure similar to PGF2a analogs, although it is not a prostaglandin, and the free acid of bimatoprost is very similar to that of latanoprost. [6] Among side effects on the eyelashes are the following: increased length, thickness and pigmentation. [7] The exact mechanism of action of prostaglandins analogs in the hair follicle is not very clear yet. It is supposed that these drugs develop eyelash hypertrichosis because they are targeted at the hair follicle prostaglandin receptor [8] and may also prolong the anagen phase of eyelashes, leading to an increase of its length. [9] Many ophthalmologists observed on several occasions the growth of eyelashes in "healthy patients" Wester et al. [10] reported a randomized controlled trial with 19 subjects. Each participant received two vials of gel suspension, which contained bimatoprost and normal saline, respectively, and labeled "right eye" and "left eye" according to randomization. The suspension was applied to the upper eyelashes every evening on the designated eye for 6 weeks. The mean eyelash regrowth from baseline in the bimatoprost group was 2.0 mm versus a mean of 1.1 mm in the placebo group, which was a statistically significant difference (P=0.009). But the importance in Dermatology is the effects of these prostaglandins analogs (latanoprost, bimatoprost and tavoprost) in eyelashes hypotrichosis as is habitual in AA [Table 1]. Coronel-Pérez et al. [4] reported a 2-year prospective study of 54 patients with AA universalis. A control group comprised of 10 subjects who received corticosteroids treatment in eyebrows and scalp, and a treatment group included 44 subjects who received the same treatment as control group and latanoprost ophthalmic solution on the eyelid margins every night. they obtained complete regrowth in 17.5% and moderate regrowth in 27.5%, so it is concluded latanoprost could be an effective drug for eyelash AA. There were no side effects. | Table 1: Summarizes all the literature on prostaglandin agonist treatment in alopecia areata
Click here to view |
Ochoa et al., [5] after Roseborough et al. reporting on a 16-week controlled study with bimatoprost and latanoprost without changes in the growth of eyelashes of the eleven patients, [11] presented a 16-week prospective study of seven patients with AA, with an application of bimatoprost ophthalmic solution once daily. The solution was well-tolerated but not effective in promoting eyelash growth in five patients with 95% or greater eyelash loss caused by AA. Authors suggest that patients with less extensive eyelash loss caused by AA may benefit from treatment with bimatoprost applied, as seen in two patients.
Zaheri and Hughes [12] reported a 16-year-old girl with AA in eyebrows and eyelashes. She applied bimatoprost cutaneouslyonce a day to the eyelids and pronounced lash growth was noted at 8 weeks.
| Conclusions | | |
We observed an acceptable response in 43.24% of patients with bilateral eyelashes AA using 0.03% bimatoprost ophthalmic solution, but we observed three patients with conjunctivitis. The limitations in this study are: we did not compare the treatment with other treatment or placebo, the subjects did not have the same basal situation, this is not a blinded study.
| References | | |
| 1. | Johnstone MA. Hypertrichosis and increased pigmentation of eyelash and adjacent hair in the región of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-7. 
|
| 2. | Woodward JA, Haggerty CJ, Stinnett SS, Williams ZY. Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement. J Cosmet Dermatol 2010;9:96-102.
|
| 3. | Sarifakioglu E, Degim IT, Gorpelioglu C. Determination of the sildenafil effect on the alopecia areata in childhood: An open-pilot comparison study. J Dermatolog Treat 2006;17:235-7.
|
| 4. | Coronel-Pérez IM, Rodríguez-Rey EM, Camacho-Martínez FM. Latanoprost in the treatment of eyelashes alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol 2010;24:481-5.
|
| 5. | Ochoa BE, Sah D, Wang G, Stamper R, Price VH. Instilled bimatoprost ophthalmic solution inpatients with eyelash alopecia areata. J Am Acad Dermatol 2009;61:530-2.
|
| 6. | Tosti A, Pazzaglia M, Voudouris S, Tosti G. Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol 2004;51:S149-50.
|
| 7. | Bikowski J, Lau EG, Jacob SE. Eyelash growth: A beneficial side effect of prostaglandin analogues. Cutis 2010;85:187-8.
|
| 8. | Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, et al. Mechanism of action of bimatoprost, latanopros, and tavoprost in healthy subjects. A crossover study. Ophtalmology 2008;115:790-5.e4.
|
| 9. | Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol 2010;4:349-58.
|
| 10. | Wester ST, Lee WW, Shi W. Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes. Ophthalmology 2010;117:1024-31.
|
| 11. | Roseborough I, Lee H, Chwalek J, Stamper RL, Price VH. Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol 2009;60:705-6.
|
| 12. | Zaheri S, Hughes B. Successful use of bimatoprost in the treatment of alopecia of the eyelashes. Clin Exp Dermatol 2010;35:e161-2.
|
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
[Table 1]
| This article has been cited by | | 1 |
Impact and Management of Loss of Eyebrows and Eyelashes |
|
| Michela Starace, Stephano Cedirian, Aurora M. Alessandrini, Francesca Bruni, Federico Quadrelli, Daniel F. Melo, Tatiana Silyuk, Andrei Doroshkevich, Bianca M. Piraccini, Matilde Iorizzo | | Dermatology and Therapy. 2023; | | [Pubmed] | [DOI] | | | 2 |
Eyebrow and Eyelash Alopecia: A Clinical Review |
|
| Betty Nguyen, Jamie Katy Hu, Antonella Tosti | | American Journal of Clinical Dermatology. 2022; | | [Pubmed] | [DOI] | | | 3 |
Uses of eye drops in dermatology, literature review |
|
| Sameh Magdy Sarsik, Heba Saed El-Amawy | | Journal of Dermatological Treatment. 2022; : 1 | | [Pubmed] | [DOI] | | | 4 |
Alopecia areata – Current understanding and management |
|
| Dimitra Aikaterini Lintzeri, Andria Constantinou, Kathrin Hillmann, Kamran Ghoreschi, Annika Vogt, Ulrike Blume- Peytavi | | JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2022; 20(1): 59 | | [Pubmed] | [DOI] | | | 5 |
Alopecia areata – Aktuelles Verständnis und Management |
|
| Dimitra Aikaterini Lintzeri, Andria Constantinou, Kathrin Hillmann, Kamran Ghoreschi, Annika Vogt, Ulrike Blume- Peytavi | | JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2022; 20(1): 59 | | [Pubmed] | [DOI] | | | 6 |
Topical bimatoprost in the treatment of eyelash loss in alopecia totalis and universalis: A prospective, open-label study |
|
| Jan Ricar, Petra Cetkovska, Maria Hordinsky, Renata Ricarova | | Dermatologic Therapy. 2022; | | [Pubmed] | [DOI] | | | 7 |
The physiological and pharmacological roles of prostaglandins in hair growth |
|
| Dong Wook Shin | | The Korean Journal of Physiology & Pharmacology. 2022; 26(6): 405 | | [Pubmed] | [DOI] | | | 8 |
Complications and Adverse Effects of Periocular Aesthetic Treatments |
|
| Sonali T. Nagendran, Mohammad Javed Ali, Murat Dogru, Raman Malhotra | | Survey of Ophthalmology. 2021; | | [Pubmed] | [DOI] | | | 9 |
Consensus on the treatment of alopecia areata – Brazilian Society of Dermatology |
|
| Paulo Müller Ramos, Alessandra Anzai, Bruna Duque-Estrada, Daniel Fernandes Melo, Flavia Sternberg, Leopoldo Duailibe Nogueira Santos, Lorena Dourado Alves, Fabiane Mulinari-Brenner | | Anais Brasileiros de Dermatologia. 2020; 95: 39 | | [Pubmed] | [DOI] | | | 10 |
Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata |
|
| Amal Ahmad El-Ashmawy, Iman Hamed El-Maadawy, Gamal Mohamed El-Maghraby | | Journal of Dermatological Treatment. 2018; 29(1): 55 | | [Pubmed] | [DOI] | | | 11 |
Bimatoprost in dermatology |
|
| AbhijeetK Jha, Rashmi Sarkar, UdayK Udayan, PK Roy, AmarK Jha, R. K. P Chaudhary | | Indian Dermatology Online Journal. 2018; 9(3): 224 | | [Pubmed] | [DOI] | | | 12 |
Promising alternative clinical uses of prostaglandin F2a analogs: Beyond the eyelashes |
|
| Young M. Choi,Joseph Diehl,Paul C. Levins | | Journal of the American Academy of Dermatology. 2015; | | [Pubmed] | [DOI] | | | 13 |
Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study |
|
| Hesham Zaher, Heba I. Gawdat, Rehab A. Hegazy, Marwa Hassan | | Dermatology. 2015; 230(4): 308 | | [Pubmed] | [DOI] | | | 14 |
Bimatoprost |
|
| Hesham Zaher,Heba Gawdat | | Journal of the Egyptian Women's Dermatologic Society. 2014; 11(2): 123 | | [Pubmed] | [DOI] | | | 15 |
Ojo y piel |
|
| J.-L. Michel | | EMC - Dermatología. 2014; 48(1): 1 | | [Pubmed] | [DOI] | | | 16 |
Alopecia Areata Update |
|
| Alkhalifah, A. | | Dermatologic Clinics. 2013; 31(1): 93-108 | | [Pubmed] | | | 17 |
La formulación magistral en la terapéutica dermatológica actual |
|
| M. Sánchez-Regaña,F. Llambí-Mateos,M. Salleras-Redonnet,M. Iglesias Sancho,H. Collgros Totosaus,P. Umbert-Millet | | Actas Dermo-Sifiliográficas. 2013; 104(9): 738 | | [Pubmed] | [DOI] | | | 18 |
Compounding as a Current Therapeutic Option in Dermatology |
|
| M. Sánchez-Regaña,F. Llambí-Mateos,M. Salleras-Redonnet,M. Iglesias Sancho,H. Collgros Totosaus,P. Umbert-Millet | | Actas Dermo-Sifiliográficas (English Edition). 2013; 104(9): 738 | | [Pubmed] | [DOI] | | | 19 |
Alopecia Areata Update |
|
| Abdullah Alkhalifah | | Dermatologic Clinics. 2012; | | [Pubmed] | [DOI] | | | 20 |
Madarosis: A marker of many Maladies |
|
| Kumar, A. and Karthikeyan, K. | | International Journal of Trichology. 2012; 4(1): 3-18 | | [Pubmed] | |
|
 |
|
|
|
